NCT04144140 is a Phase 1 clinical trial of E7766 in Lymphoma, sponsored by Eisai Inc..

Who is sponsoring NCT04144140?

NCT04144140 is sponsored by Eisai Inc..

What drugs are being tested in NCT04144140?

Interventions in NCT04144140: E7766.

What condition does NCT04144140 study?

NCT04144140 studies Lymphoma, Advanced Solid Tumors.

Is NCT04144140 still recruiting?

NCT04144140 is currently terminated. Last updated 7 March 2024.

Are results published for NCT04144140?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-03-07 · How we verify

NCT04144140

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Terminated Phase 1 Results posted Last updated 7 March 2024

What this trial tests

Phase 1 trial testing E7766 in Lymphoma in 24 participants. Terminated before completion.

Timeline

24 February 2020

Primary endpoint
26 July 2022

26 July 2022

Quick facts

Lead sponsor	Eisai Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	24 February 2020
Primary completion	26 July 2022
Estimated completion	26 July 2022
Sites	13 locations across France, United Kingdom, South Korea, United States, Spain

Drugs / interventions tested

E7766 — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →
Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Eisai Inc. — full company profile →

Who can join

18 and older, any sex, with Lymphoma or Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Dose Escalation Part: Number of Participants With Dose-limiting Toxicities (DLTs) Primary · Cycle 1 (Cycle length= 21 days)

DLTs were predefined as any of the following toxicities occurring during Cycle 1 and were assessed by the investigator according to National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version (v) 5.0. as related to E7766. Nonhematologic toxicity greater than or equal to (\>=) Grade 3 (NCI CTCAE v. 5.0), except Grade 3 fatigue less than (\<) 5 days. Asymptomatic Grade 3 or 4 laboratory abnormalities that were corrected within 72 hours. \>=Grade 3 nausea, vomiting, and diarrhea unless lasting greater than (\>) 48 hours despite optimal supportive care. Hemat

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	0
Dose Escalation Part: E7766 150 mcg	0
Dose Escalation Part: E7766 300 mcg	0
Dose Escalation Part: E7766 600 mcg	2
Dose Escalation Part: E7766 780 mcg	1

Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) Primary · From the first dose of the study drug up to 90 days after the last dose (up to 9 months and 14 days)

A TEAE was defined as an adverse event (AE) that emerges during treatment (on or after the first dose of study drug up to 90 days after the participant's last dose) or start day of another anticancer therapy, whichever is earlier; or in case participant has initiated new anticancer therapy within 30 days, then AEs occurring for 30 days following the last dose of E7766, having been absent at pretreatment (Baseline) or reemerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsens in severity during treatment relative to the pretreatment state

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	2
Dose Escalation Part: E7766 150 mcg	2
Dose Escalation Part: E7766 300 mcg	2
Dose Escalation Part: E7766 600 mcg	11
Dose Escalation Part: E7766 780 mcg	6
Dose Escalation Part: E7766 1000 mcg	1

Dose Escalation Part: ORR Based on iRECIST Secondary · From date of first dose of study drug until confirmed iCR or iPR (up to 6 months and 18 days)

ORR was defined as the percentage of participants whose BOR was iCR or iPR according to iRECIST as per investigator assessment. iCR: immune complete response achieved with disappearance of all target lesions iCPD: immune confirmed progressive disease when there is either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions iSD: immune stable disease in the absence of iCR or iPD iUPD: immune unconfirmed progressive disease when iPD is unconfirmed NE: not evaluable.

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	0
Dose Escalation Part: E7766 150 mcg	0
Dose Escalation Part: E7766 300 mcg	0
Dose Escalation Part: E7766 600 mcg	0
Dose Escalation Part: E7766 780 mcg	0
Dose Escalation Part: E7766 1000 mcg	0

Dose Escalation Part: ORR Based on mRECIST v1.1 Secondary · From date of first dose of study drug until confirmed CR or PR (up to 6 months and 18 days)

ORR was defined as the percentage of participants with a BOR of CR or PR for target and non-target lesions. CR was defined as the disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in the short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The tumor assessment was done using number of lesions based on modified RECIST 1.1 as per investigator assessment for assessing tumor burden up to 10 target lesions w

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	0
Dose Escalation Part: E7766 150 mcg	0
Dose Escalation Part: E7766 300 mcg	0
Dose Escalation Part: E7766 600 mcg	0
Dose Escalation Part: E7766 780 mcg	0
Dose Escalation Part: E7766 1000 mcg	0

Dose Escalation Part: DCR Based on iRECIST Secondary · From first dose of study drug until confirmed iCR or iPR or >=5 weeks after first dose for iSD (up to 6 months and 18 days)

DCR: percentage of participants with a confirmed iCR, iPR, or i-SD (duration of iSD \>=5 weeks). DCR was assessed on iRECIST v1.1 as per investigator assessment. iCR: immune complete response achieved with disappearance of all target lesions iCPD: immune confirmed progressive disease when there is either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions iSD: immune stable disease in the absence of iCR or iPD iUPD: immune unconfirmed progressive disease when iPD is unconfirmed NE: not evaluable.

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	100.0
Dose Escalation Part: E7766 150 mcg	0.0
Dose Escalation Part: E7766 300 mcg	50.0
Dose Escalation Part: E7766 600 mcg	36.4
Dose Escalation Part: E7766 780 mcg	16.7
Dose Escalation Part: E7766 1000 mcg	0.0

Dose Escalation Part: DCR Based on mRECIST v1.1 Secondary · From first dose of study drug until confirmed CR or PR or >=5 weeks after first dose for SD (up to 6 months and 18 days)

DCR was defined as the percentage of participants with a best overall response of CR or PR, or SD based on mRECIST 1.1 as per investigator assessment. Best overall response of SD must have been \>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target les

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	100.0
Dose Escalation Part: E7766 150 mcg	0.0
Dose Escalation Part: E7766 300 mcg	50.0
Dose Escalation Part: E7766 600 mcg	36.4
Dose Escalation Part: E7766 780 mcg	16.7
Dose Escalation Part: E7766 1000 mcg	0.0

Cmax: Maximum Observed Plasma Concentration for E7766 Secondary · Dose Escalation: Cycle 1 Days 1 and 15: predose and up to 24 hours postdose; Dose Expansion: Cycle 1 Days 1 and 15: predose up to 2 hours postdose (Cycle length=21 days)

Cmax was quantified using liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	4.23	± 87.4
Dose Escalation Part: E7766 150 mcg	2.77	± 7.16
Dose Escalation Part: E7766 300 mcg	2.95	± 9.85
Dose Escalation Part: E7766 600 mcg	8.03	± 95.8
Dose Escalation Part: E7766 780 mcg	11.3	± 30.6
Dose Escalation Part: E7766 1000 mcg	9.99	± NA

Cycle 1 Day 15

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	1.29	± 22.7
Dose Escalation Part: E7766 150 mcg	2.23	± 58.1
Dose Escalation Part: E7766 300 mcg	4.53	± NA
Dose Escalation Part: E7766 600 mcg	2.72	± 168
Dose Escalation Part: E7766 780 mcg	9.33	± 34.8

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7766 Secondary · Dose Escalation: Cycle 1 Days 1 and 15: predose and up to 24 hours postdose; Dose Expansion: Cycle 1 Days 1 and 15: predose up to 2 hours postdose (Cycle length=21 days)

Tmax was quantified using validated liquid LC-MS/MS methods.

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	0.275	0.25 – 0.3
Dose Escalation Part: E7766 150 mcg	0.31	0.27 – 0.35
Dose Escalation Part: E7766 300 mcg	0.275	0.25 – 0.3
Dose Escalation Part: E7766 600 mcg	0.25	0.2 – 0.52
Dose Escalation Part: E7766 780 mcg	0.25	0.2 – 0.28
Dose Escalation Part: E7766 1000 mcg	0.28	0.28 – 0.28

Cycle 1 Day 15

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	0.215	0.18 – 0.25
Dose Escalation Part: E7766 150 mcg	0.385	0.27 – 0.5
Dose Escalation Part: E7766 300 mcg	0.25	0.25 – 0.25
Dose Escalation Part: E7766 600 mcg	0.25	0.17 – 23.4
Dose Escalation Part: E7766 780 mcg	0.21	0.2 – 0.25

Part: AUC(0-t): Area Under the Plasma Concentration From Time Zero to Last Curve for E7766 Secondary · Dose Escalation: Cycle 1 Days 1 and 15: predose and up to 24 hours postdose; Dose Expansion: Cycle 1 Days 1 and 15: predose up to 2 hours postdose (Cycle length=21 days)

AUC was quantified using validated liquid LC-MS/MS methods.

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	2.71	± 114.0
Dose Escalation Part: E7766 150 mcg	3.42	± 64.7
Dose Escalation Part: E7766 300 mcg	4.25	± 26.6
Dose Escalation Part: E7766 600 mcg	7.7	± 35.9
Dose Escalation Part: E7766 780 mcg	8.29	± 44.2
Dose Escalation Part: E7766 1000 mcg	10.3	± NA

Cycle 1 Day 15

Group	Value	95% CI
Dose Escalation Part: E7766 75 mcg	0.536	± 17.0
Dose Escalation Part: E7766 150 mcg	1.95	± 29.4
Dose Escalation Part: E7766 300 mcg	5.51	± NA
Dose Escalation Part: E7766 600 mcg	4.06	± 101.0
Dose Escalation Part: E7766 780 mcg	6.89	± 76.9

AUC(0-inf): Area Under the Plasma Concentration From Time Zero to Infinity Curve for E7766 Secondary · Dose Escalation: Cycle 1 Days 1 and 15: predose and up to 24 hours postdose; Dose Expansion: Cycle 1 Days 1 and 15: predose up to 2 hours postdose (Cycle length=21 days)

AUC(0-inf) was quantified using liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation Part: E7766 150 mcg	5.58	± NA
Dose Escalation Part: E7766 300 mcg	4.64	± 25.1
Dose Escalation Part: E7766 600 mcg	8.07	± 38.5
Dose Escalation Part: E7766 780 mcg	8.93	± 54.9
Dose Escalation Part: E7766 1000 mcg	10.4	± NA

Cycle 1 Day 15

Group	Value	95% CI
Dose Escalation Part: E7766 150 mcg	2.18	± 35.4
Dose Escalation Part: E7766 300 mcg	5.79	± NA
Dose Escalation Part: E7766 600 mcg	5.16	± 83.6
Dose Escalation Part: E7766 780 mcg	7.07	± 75.7

t1/2: Terminal Elimination Half-life for E7766 Secondary · Dose Escalation: Cycle 1 Days 1 and 15: predose and up to 24 hours postdose; Dose Expansion: Cycle 1 Days 1 and 15: predose up to 2 hours postdose (Cycle length=21 days)

t1/2 was quantified using validated liquid LC-MS/MS methods.

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation Part: E7766 150 mcg	1.56	± NA
Dose Escalation Part: E7766 300 mcg	1.07	± 4.61
Dose Escalation Part: E7766 600 mcg	1.18	± 36.9
Dose Escalation Part: E7766 780 mcg	1.15	± 17.5
Dose Escalation Part: E7766 1000 mcg	1	± NA

Cycle 1 Day 15

Group	Value	95% CI
Dose Escalation Part: E7766 150 mcg	0.956	± 58.1
Dose Escalation Part: E7766 300 mcg	0.917	± NA
Dose Escalation Part: E7766 600 mcg	1.34	± 66.7
Dose Escalation Part: E7766 780 mcg	0.723	± 59.5

Dose Escalation Part: CL/F: Apparent Total Body Clearance for E7766 Secondary · Dose Escalation: Cycle 1 Days 1 and 15: predose and up to 24 hours postdose (Cycle length=21 days)

CL/F was quantified using validated liquid LC-MS/MS methods.

Cycle 1 Day 1

Group	Value	95% CI
Dose Escalation Part: E7766 150 mcg	26.9	± NA
Dose Escalation Part: E7766 300 mcg	64.6	± 25.2
Dose Escalation Part: E7766 600 mcg	74.4	± 38.5
Dose Escalation Part: E7766 780 mcg	87.3	± 54.8
Dose Escalation Part: E7766 1000 mcg	90.3	± NA

Cycle 1 Day 15

Group	Value	95% CI
Dose Escalation Part: E7766 150 mcg	68.7	± 35.3
Dose Escalation Part: E7766 300 mcg	51.8	± NA
Dose Escalation Part: E7766 600 mcg	116.0	± 83.7
Dose Escalation Part: E7766 780 mcg	110.0	± 75.9

Adverse events — posted to ClinicalTrials.gov

Time frame: Dose Escalation Part: From the first dose of the study drug up to 90 days after the last dose (up to 9 months and 14 days). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Dose Escalation Part: E7766 75 mcg

Serious: 0/2 (0%)

Deaths: 1/2

Dose Escalation Part: E7766 150 mcg

Serious: 0/2 (0%)

Deaths: 1/2

Dose Escalation Part: E7766 300 mcg

Serious: 1/2 (50%)

Deaths: 1/2

Dose Escalation Part: E7766 600 mcg

Serious: 3/11 (27%)

Deaths: 4/11

Dose Escalation Part: E7766 780 mcg

Serious: 3/6 (50%)

Deaths: 5/6

Dose Escalation Part: E7766 1000 mcg

Serious: 1/1 (100%)

Deaths: 1/1

Serious adverse events (10 terms)

Reaction	System	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—
Localised oedema	General disorders	—	—	—	—	—	—
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Cerebral venous sinus thrombosis	Nervous system disorders	—	—	—	—	—	—
Confusional state	Psychiatric disorders	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—

Other adverse events (98 terms — click to expand)

Reaction	System	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…	Dose Escalation Part: E776…
Chills	General disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—
Injection site reaction	General disorders	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—
Anaemia of malignant disease	Blood and lymphatic system disorders	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—
Atrial flutter	Cardiac disorders	—	—	—	—	—	—
Bradycardia	Cardiac disorders	—	—	—	—	—	—
Sinus bradycardia	Cardiac disorders	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—
Ear pain	Ear and labyrinth disorders	—	—	—	—	—	—
Tinnitus	Ear and labyrinth disorders	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—
Lacrimation increased	Eye disorders	—	—	—	—	—	—

Most-reported serious reactions: Small intestinal obstruction, Upper gastrointestinal haemorrhage, Vomiting, Injection site pain, Localised oedema, Tumour pain, Cerebral venous sinus thrombosis, Confusional state.

Data from ClinicalTrials.gov NCT04144140 adverse events section.

Sponsor's own description

This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation and tumor progression: signaling pathways and targeted intervention.
Zhao H, Wu L, Yan G, Chen Y, et al · · 2021 · cited 1932× · PMID 34248142 · DOI 10.1038/s41392-021-00658-5
cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M, Chen P, Wang L, Li W, et al · · 2020 · cited 420× · PMID 32571374 · DOI 10.1186/s13045-020-00916-z
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Melero I, Castanon E, Alvarez M, Champiat S, et al · · 2021 · cited 358× · PMID 34006998 · DOI 10.1038/s41571-021-00507-y
STING Agonists as Cancer Therapeutics.
Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, et al · · 2021 · cited 311× · PMID 34070756 · DOI 10.3390/cancers13112695
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
cGAS-STING pathway in cancer biotherapy.
Wang Y, Luo J, Alu A, Han X, et al · · 2020 · cited 255× · PMID 32887628 · DOI 10.1186/s12943-020-01247-w
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
Garland KM, Sheehy TL, Wilson JT. · · 2022 · cited 250× · PMID 35107989 · DOI 10.1021/acs.chemrev.1c00750
The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.
Oduro PK, Zheng X, Wei J, Yang Y, et al · · 2022 · cited 231× · PMID 35127372 · DOI 10.1016/j.apsb.2021.05.011

Verify or expand the search:

Other trials of E7766

Trials testing the same drug.

NCT04109092 — A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including · Phase 1 · withdrawn

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Eisai Inc. trials

Trials by the same sponsor.

NCT07493265 — A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy · Phase 2 · not yet recruiting
NCT07308236 — A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants · Phase 1 · recruiting
NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
NCT06744673 — A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control P · active not recruiting
NCT06602258 — A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04144140 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Inc.
Last refreshed: 7 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04144140.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04144140

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (10 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of E7766

Other recruiting trials for Lymphoma

Other Eisai Inc. trials

Verify against primary sources